Resverlogix rises 45% after second RVX-208 analysis rescue attempt
This article was originally published in Scrip
Executive Summary
For the second time in recent months, Resverlogix has seen a huge leap in its share price on the back of an analysis of Phase IIb studies of its failed cardiovascular drug RVX-208. The Canadian company, which has staked everything on RVX-208, commissioned an independent firm to analyze data from the ASSURE and SUSTAIN studies in a seemingly desperate bid to convince stakeholders of the drug's worth.